

4
7/11/03**Martin A. Hay & Co.**

FAX RECEIVED

JUL 07 2003

13 Queen Victoria Street
Macclesfield
Cheshire SK11 6LP
UNITED KINGDOMTel: (+44) 1625 500057
Fax: (+44) 1625 500058

GROUP 1600

E-mail: martinahay@martin-a-hay.com

FACSIMILE TRANSMITTAL SHEET

OFFICIAL

Date: 4th July 2003 **Total Number of Pages:** 11
(including cover page)

To: Commissioner for Patents
US Patent & Trademark Office

FAX Number: 001 703 308 4556

From: Martin A Hay

FAX Number: (44) 1625 500058


Acknowledgment Requested: Yes No

Message:

Re: Applicant: Liebeschuetz et al
US Application Serial No. 10/030,188
Our Ref: 00217/US

NOTE:

This facsimile is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please telephone (44) 1625 500057 collect.

CERTIFICATION OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
<u>MARTIN A. HAY</u> Type or print name of person signing certification	
 Signature	<u>July 4, 2003</u> Date

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : LIEBESCHUETZ, John Walter
MURRAY, Christopher William
YOUNG, Stephen Clinton
CAMP, Nicholas Paul
JONES, Stuart Donald
WYLIE, William Alexander
MASTERS, John Joseph
WILEY, Michael Robert
SHEEHAN, Scott Martin
ENGEL, David Birenbaum
WATSON, Brian Morgan

Serial No. : 10/030,188 ✓

Filed : 04 February 2002 ✓

Group Art Unit: 1624

Examiner : PATEL, Sudhaker B

For : Serine Protease Inhibitors ✓

Docket No. : 00217/US

By Facsimile (without Copies of References)

Confirmation (with Copies of References) by Courier

Serial No. 10/030,188

Commissioner for Patents
US Patent & Trademark Office
2011 South Clark Place
Customer Window
Crystal Plaza Two, Lobby, Room 1B03
UNITED STATES

Sir:

INFORMATION DISCLOSURE STATEMENT

As a means of complying with the duty of disclosure, Applicant's submit an "Information Disclosure Statement by Applicant" on PTO Form PTO/SB/08A for consideration by the Examiner. Since this statement is being submitted during the period specified in 37 C.F.R. § 1.97(b), it is believed that no fee is due for this submission. However, should an Office Action on the merits have been mailed, please charge Deposit Account No. 50-1230 in the amount of the fee under 37 C.F.R. § 1.17(p), and consider the information under 37 C.F.R. § 1.97(c).

It is understood that the Examiner has received a copy of the International Search Report and copies of the documents cited therein (Documents B1, B2, B4, B5 and B21). If this is incorrect, the Examiner is kindly requested to contact the undersigned to request copies.

Document A2, which issued in April, 2003, claims priority from the same US provisional application as Document B18.

In addition, Applicants would like to provide the Examiner with the following background information:-

Serial No. 10/030,188

BACKGROUND INFORMATION

This application claims priority under 35 U.S.C. 119 from PCT/GB00/02302 (WO 00/76971, Document (B4)), which has entered the U.S. national stage as U.S. patent application serial number 09/926,712. The claims in the 09/926,712 application have been amended so as not to read on any of the compounds originally claimed in the present application.

The compounds claimed in this application were invented in the course of a research collaboration between Eli Lilly and Company (the assignee of record) and Protherics Molecular Design Limited (now Tularik Limited, a subsidiary of Tularik Inc). The predecessor company of Protherics Molecular Design Limited was Proteus Molecular Design Limited. By virtue of an agreement dated December 15, 1999, the invention claimed in the present application was subject to an obligation of assignment to Eli Lilly and Company at the time that the invention was made.

This application forms part of a portfolio of patent applications directed to serine protease inhibitors, some of which belong to Eli Lilly and Company, and some of which belong to Tularik Limited. The history of this portfolio traces back to a research project on serine protease inhibitors started by Proteus Molecular Design Limited. The undersigned is responsible for handling the applications in this portfolio.

A listing of the co-pending applications and patents in the portfolio is attached.

Eli Lilly and Company also owns a separate portfolio of applications and patents relating to serine protease inhibitors. PCT references belonging to this portfolio are


Serial No. 10/030,188

listed in the attached form PTO/SB/08A. Generally these PCT references have U.S. counterparts.

COMMUNICATION BY TELEPHONE

If the Examiner wishes to speak by telephone with the undersigned, the undersigned can be contacted by e-mail at martinahay@martin-a-hay.com, and would be pleased to telephone the Examiner in response.

Respectfully submitted,



Hay, Martin Alexander

Agent for Applicants

Registration No. 39,459

Phone: 011 44 1625 500057

e-mail: martinahay@martin-a-hay.com

Martin A. Hay & Co.,
13 Queen Victoria Street
Macclesfield
Cheshire
SK11 6LP
UNITED KINGDOM

July 4, 2003

Serial No. 10/030,188

Co-Pending Lilly and Tularik Applications and Patents

Co-pending applications - Assigned to Eli Lilly and Company

09/926,712 (national stage of WO 00/76971 (B4))
09/926,716 (national stage of WO 00/76970 (B5) - abandoned)
10/030,187 (national stage of WO 01/96323)
10/030,186 (national stage of WO 01/96304)
10/030,189 (national stage of WO 01/96296)

4. Co-pending applications and patents - Assigned to Tularik Limited

US 6262069 and US 6420438 (national stage of WO 99/11657 (B1) and continuation)
09/988,082 (continuation-in-part of 09/485,678, WO 99/11658 (B2) and of WO 00/77027 (B6))
10/148,174 (national stage of WO 01/44226)
10/296,245 (national stage of WO 01/96305)
10/432,365 (national stage of WO 02/47762)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 144B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	5
-------	---	----	---

Complete if Known

Application Number	10/030,188
Filing Date	02/04/2002
First Named Inventor	Liebeschuetz, J. W.
Art Unit	1624
Examiner Name	Patel, Sudhaker B
Attorney Docket Number	00217/US

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ²
		Country Code* ² Number* ³ Kind Code* ⁴ (if known)	MM-DD-YYYY			
	B1	WO 99/11657	03-11-1999	Proteus		
	B2	WO 99/11658	03-11-1999	Proteus		
	B3	WO 98/47876	10-29-1998	Akzo		
	B4	WO 00/76971	12-21-2000	Eli Lilly and Co		
	B5	WO 00/76970	12-21-2000	Eli Lilly and Co		
	B6	WO 00/77027	12-21-2000	Protherics		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

18/10

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known

(Use as many sheets as necessary)

Sheet	2	of	5
-------	---	----	---

Application Number	10/030,188
Filing Date	02/04/2002
First Named Inventor	Liebeschuetz, J. W.
Art Unit	1624
Examiner Name	Patel, Sudhaker B
Attorney Docket Number	00217/US

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code* Number* Kind Code* (if known)	MM-DD-YYYY			
	B7	WO 91/00725	01-24-1991	Abbott Labs		
	B8	WO 99/00121	01-07-1999	Eli Lilly and Co		
	B9	WO 99/00126	01-07-1999	Eli Lilly and Co		
	B10	WO 99/00127	01-07-1999	Eli Lilly and Co		
	B11	WO 99/00128	01-07-1999	Eli Lilly and Co		
	B12	WO 00/39092	07-06-2000	Eli Lilly and Co		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

122p

